首页 >> 科学研究 >> 研究中心 >> 正文


多肽功能材料与创新药物研究中心

创建时间:  2023/03/02  马晓宇   浏览次数:   返回

研究方向:

1.多肽探针与智能诊断

2.多肽材料与再生修复

3.多肽药物与安全治疗


研究中心主任:

石业娇 副研究员、博士研究生导师


研究中心副主任:

何世鹏 副研究员、博士研究生生导师


研究中心成员:



undefined

高飞 副研究员、硕士研究生导师


研究中心代表作:

1. Yejiao Shi, Peter A. Summers, Marina K. Kuimova, and Helena S. Azevedo, Unravelling the Enzymatic Degradation Mechanism of Supramolecular Peptide Nanofibers and Its Correlation with Their Internal Viscosity, Nano Lett. 2020, 20, 10,7375–7381.(IF=16.262)

2. Yejiao Shi, David W. Wareham, Yichen Yuan, Xinru Deng, Alvaro Mata, Helena S. Azevedo, Polymyxin B-Triggered Assembly of Peptide Hydrogels for Localized and Sustained Release of Combined Antimicrobial Therapy, Adv Healthc Mater.2021 Nov;10(22):e2101465.(IF=11.092)

3. Shipeng He, Fei Gao, Junhui Ma, Haoqian Ma, Guoqiang Dong, Chunquan Sheng, Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer, Angew Chem Int Ed Engl. 2021 Oct 18;60(43):23299-23305.(IF=16.823)

4. Shipeng He, Guoqiang Dong, Yu Li, Shanchao Wu, Wei Wang, Chunquan Sheng, Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer, Angew Chem Int Ed Engl. 2020 Feb 17;59(8):3028-3032.(IF=16.823)

5. Shipeng He, Junhui Ma, Yuxin Fang, Ying Liu, Shanchao Wu, Guoqiang Dong, Wei Wang, Chunquan Sheng, Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer, Acta Pharm Sin B. 2021 Jun;11(6):1617-1628.(IF=14.903)

6. Fei Gao, Jinming Zhou, Yang Sun, Cai Yang, Shiyan Zhang, Ruowen Wang, Weihong Tan, Programmable Repurposing of Existing Drugs as Pharmaceutical Elements for the Construction of Aptamer–Drug Conjugates, ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9457-9463.(IF=10.383)

7. Minghao Wu, Shipeng He, Hua Tang, Honggang Hu, Yejiao Shi, Molecular Engineering of Polymyxin B for Imaging and Treatment of Bacterial Infections, Front Chem. 2022 Jan 7;9:809584.(IF=5.545)

8. Fei Gao, Jianhui Yin, Yan Chen, Changyong Guo, Honggang Hu, Jiacan Su, Recent advances in aptamer-based targeted drug delivery systems for cancer therapy, Front Bioeng Biotechnol. 2022 Aug 16;10:972933.(IF=6.064)

9. Xiaoyuan Zhao, Shipeng He, Bo Li, Bin Liu, Yejiao Shi, Wei Cong, Fei Gao, Jingjing Li, Fan Wang, Kai Liu, Chunquan Sheng, Juanjuan Su, Hong-Gang Hu, DUCNP@Mn-MOF/FOE as a Highly Selective and Bioavailable Drug Delivery System for Synergistic Combination Cancer Therapy, Nano Lett. 2023 Feb 8;23(3):863-871.(IF=12.262)

10. Xiaoyuan Zhao, Xiang Li, Bo Li, Yao Sun, Yejiao Shi, Huaxing Shen, Fan Wang, Jingjing Li, Farukh Sharopov, Zainiddin Mukhiddinov, Chao Ma, Kai Liu, Hong-Gang Hu, A robust protein-peptide co-assembling nanoformulation (PePCAN) platform with significant cell-entry characteristics for targeted cancer therapy, Chemical Engineering Journal, 2023, 139886.(IF=13.273)

上一条:未来细胞分析中心

下一条:衰老机制与药物创新研究中心